




43. A compound of claim 1, selected from the group consisting of:




44. A compound of claim 1, selected from the group consisting of:



45. A compound of claim 1, selected from the group consisting of:



and



2

1

2

506

32

46. A composition comprising a pharmaceutically acceptable excipient and a compound of any of claims 1-45.

1

2

3

47. A method for modulating conditions associated with metabolic or inflammatory disorders in a host, said method comprising administering to said host an efficacious amount of a compound of any of claims 1-45.

1

2

3

48. A method in accordance with claim 47, wherein said host is a mammal selected from the group consisting of humans, dogs, monkeys, mice, rats, horses and cats.

1

2

49. A method in accordance with claim 47, wherein said administering is oral.

1

2

50. A method in accordance with claim 47, wherein said administering is topical.

1

2

51. A method in accordance with claim 47, wherein said administering is prophylactic to prevent the onset of a PPAR γ -mediated condition.

1

2

3

52. A method in accordance with claim 47, wherein said disorders are selected from the group consisting of NIDDM, obesity, hypercholesterolemia and other lipid-mediated diseases, and inflammatory conditions.

1

2

53. A method in accordance with claim 47, wherein said administering is parenteral.